STEAP1: STEAP1 protein
Does not function as a metalloreductase due to the absence of binding sites for the electron-donating substrate NADPH.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on STEAP1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody-drug conjugate 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Vandortuzumab vedotin | Phase 2 | Roche | Antibody-drug conjugate | Binding agentMetalloreductase STEAP1 binding agent | 0 |
- Type 2 diabetes mellitus0.43
- Diabetes mellitus0.36
- Thrombophilia0.33
- Neurodegenerative disease0.27
- Brain cancer0.22
- Smoking initiation0.20
- Cardiac transplant0.18
- Abnormal pupillary function0.18
- Placenta praevia0.18
- Sign or symptom0.18
- Preeclampsia0.18
- Type 1 diabetes mellitus0.16
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712956, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q9UHE8, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets